Virpax Pharmaceuticals, Inc.
VRPX
Rank in Stocks
#34926
Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical... Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical enterprise, dedicated to pioneering diverse drug-delivery systems and novel drug-releasing technologies. Its core focus lies in developing advanced, non-opioid and non-addictive solutions for pain management, alongside therapies targeting central nervous system disorders. The company's current investigational pipeline features several preclinical product candidates. These include Epoladerm, a topical nonsteroidal anti-inflammatory drug (NSAID) designed to address chronic osteoarthritis of the knee, and Probudur, an injectable liposomal gel formulated as a local anesthetic for managing post-operative pain. Also in development are Envelta and PES200, both nanotechnology-based intranasal spray drug candidates engineered to deliver metabolically labile peptide drugs directly to the brain. Further candidates comprise AnQlar, an antiviral barrier solution intended to prevent or lessen the severity of human viral infections such as influenza and SARS-CoV-2, and VRP324, an experimental nasal formulation aimed at enhancing the transport of cannabidiol into the brain. Virpax Pharmaceuticals, Inc. was established in 2016 and is based in Berwyn, Pennsylvania.
Share Price
$0.001
Last synced: 2026-11-09
Market Cap
$1.24K
Change (1 day)
-50.00%
Change (1 year)
-95.24%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Virpax Pharmaceuticals, Inc. (VRPX)
Category
Healthcare
EPS for Virpax Pharmaceuticals, Inc. (VRPX)
EPS as of December 2024 TTM: $-5.73
According to Virpax Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-5.73. At the end of 2024 the company had an EPS of $-70.91, a decrease compared to its 2023 EPS of $-12.97.
EPS history for Virpax Pharmaceuticals, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-5.73 | -91.92% |
| 2024 | $-70.91 | 446.72% |
| 2023 | $-12.97 | -29.20% |
| 2022 | $-18.32 | 76.66% |
| 2021 | $-10.37 | 14.33% |
| 2020 | $-9.07 | 37.84% |
| 2019 | $-6.58 | 1,141.51% |
| 2018 | $-0.53 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -373.30% |
US
|
|
| $-7.07 | 23.39% |
US
|
|
| $-5.29 | -7.68% |
AU
|
|
| $12.88 | -324.78% |
BE
|
|
| $21.56 | -476.27% |
NL
|
Questions about Virpax Pharmaceuticals, Inc.'s earnings per share (EPS)
What is Virpax Pharmaceuticals, Inc.'s earnings per share (EPS)?
Virpax Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-5.73, as of Dec 2024.
What was Virpax Pharmaceuticals, Inc.'s earnings per share (EPS) in 2024?
In 2024, Virpax Pharmaceuticals, Inc.'s earnings per share (EPS) was $-70.91, compared with $-12.97 in 2023.
How has Virpax Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2019?
From 2019 to 2024, Virpax Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2019 ($-6.58) and lowest in 2024 ($-70.91).
How does Virpax Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
Virpax Pharmaceuticals, Inc.'s earnings per share (EPS) ($-5.73) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.